Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.
Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune disease, Alzheimer’s and Parkinson’s disease, among others.
Evotec International GmbH has reported new prodrugs of NLRP3 inflammasome inhibitors potentially useful for the treatment of inflammation, asthma, hypertension, myocardial infarction, neurological disorders, silicosis, graft-vs.-host and metabolic diseases.
Insilico Medicine Inc. has reported new NLRP3 inflammasome inhibitors potentially useful for the treatment of obesity, autoimmune and autoinflammatory diseases.
Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others.
The aberrant activation of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a known crucial driver of neuroinflammation in Alzheimer’s disease (AD) and other related dementias. The inhibition of NLRP3 has shown benefits in preclinical models. Researchers from the University of Texas recently presented data regarding an NLRP3 inhibitor, AMS-17, for the treatment of AD and related dementias.
Zhejiang Pantheon Innovation Pharmaceutical Co. Ltd. has disclosed prodrugs of an NLRP3 inflammasome inhibitor compound. They are reported to be useful for the treatment of cancer and inflammation.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, cardiometabolic syndrome, cardiovascular disorders, Parkinson’s disease and Alzheimer’s disease.
Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed pyroptosis and NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, gout, inflammatory disorders, multiple sclerosis, psoriasis, autoimmune diseases and Alzheimer’s disease.
